Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Dimethyl fumarate

Dimethyl fumarate: 1 brand, 17 generics; first approved Mar 27, 2013; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 17 ANDA applications approved.

Earliest patent expiry
Brands (NDA)
1
Generics (ANDA)
17
Listed patents
9
Next patent expiry
Feb 07, 2028
in 1 yr 6 mo

Brand (NDA) products

Originator applications
  • NDA 20406320132 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB

Generic (ANDA) products (17)

Abbreviated applications
  • DIMETHYL FUMARATE
    ANDA 21039020252 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALDiscontinued
    240MGCAPSULE, DELAYED RELEASEORALDiscontinued
  • DIMETHYL FUMARATE
    ANDA 21037720242 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21038520222 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21041420222 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21028520212 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALDiscontinued
    240MGCAPSULE, DELAYED RELEASEORALDiscontinued
  • DIMETHYL FUMARATE
    ANDA 21043620212 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21038220202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21030920202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21022620202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21049920202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21044020202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21040220202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21030520202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALDiscontinued
    240MGCAPSULE, DELAYED RELEASEORALDiscontinued
  • DIMETHYL FUMARATE
    ANDA 21050020202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21046020202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALRxAB
    240MGCAPSULE, DELAYED RELEASEORALRxAB
  • DIMETHYL FUMARATE
    ANDA 21053820202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALDiscontinued
    240MGCAPSULE, DELAYED RELEASEORALDiscontinued
  • DIMETHYL FUMARATE
    ANDA 21053120202 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    120MGCAPSULE, DELAYED RELEASEORALDiscontinued
    240MGCAPSULE, DELAYED RELEASEORALDiscontinued

Patent & exclusivity timeline

Protection horizon
20262027202820292030203120322033203420352036TodayPatent 8399514: 2028-02-07Patent 8399514Patent 10391160: 2035-03-13Patent 10391160Patent 10555993: 2035-03-13Patent 10555993Patent 10994003: 2035-03-13Patent 10994003Patent 10959972: 2035-11-16Patent 10959972Patent 11129806: 2035-11-16Patent 11129806Patent 11007166: 2035-11-16Patent 11007166Patent 11007167: 2035-11-16Patent 11007167Patent 11246850: 2035-11-16Patent 11246850
Patent expiryExclusivity endToday

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8399514in 1 yr 6 mo
U-1384
10391160in 8 yr 9 mo
U-3148
10555993in 8 yr 9 mo
U-3148
10994003in 8 yr 9 mo
U-3148
10959972in 9 yr 5 mo
U-1384
11129806in 9 yr 5 mo
U-1384
11007166in 9 yr 5 mo
U-1384
11007167in 9 yr 5 mo
U-1384
11246850in 9 yr 5 mo
U-1384

Approval history

FDA approval span
First approval
13 yr 7 mo ago
Most recent approval
1 yr 7 mo ago

Approvals span 2013–2025 across 18 FDA applications.

Brand (NDA) 16%
Generic (ANDA) 1794%

Dimethyl fumarate: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.